Viking Therapeutics’ Obesity Drug Shows Durable Weight-Loss Benefit, Shares Jump
The company said 180 adults with obesity maintained up to 97% of prior weight loss on every-other-week dosing and up to 90% on monthly dosing.
- On Tuesday, Viking Therapeutics announced positive top-line results from its VK2735-102 maintenance study, showing patients maintained significant weight loss after transitioning to less frequent dosing regimens.
- Following an initial 21-week induction period of weekly injections, the trial transitioned participants to monthly or every-other-week doses of VK2735 to evaluate long-term weight management and treatment adherence.
- Patients switching to every-other-week dosing maintained up to 97% of weight loss, while those on monthly dosing retained up to 90% over the following 12 weeks.
- "These results are important as they provide a basis for improved dosing flexibility," said Louis Aronne, MD, FACP, former president of The Obesity Society, noting excellent tolerability with GI-related adverse event rates similar to placebo.
- Analysts expect the obesity market to reach $100 billion in annual sales by 2030, as Viking prepares to study oral maintenance dosing in an upcoming trial to expand patient options.
10 Articles
10 Articles
Viking Therapeutics' obesity drug shows durable weight-loss benefit ...
Viking Therapeutics VK2735 Obesity Drug Maintains Weight Loss Up to 97% as Shares Surge 40%
Viking Therapeutics said patients shifted to a less frequent dosing regimen of its experimental obesity treatment showed superior weight loss maintenance to those on placebo, in a study, sending its shares up 40% before the bell.The company said on Tuesday that patients who switched to an every-other-week dosing of VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period, while those on a monthly dosi…
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed Results Demonstrate Viability of Monthly...
Viking Therapeutics, which is seen as a potential future competitor to Novo Nordisk and Eli Lilly in the obesity market, surged nearly 30 percent in US pre-market trading on Tuesday after positive study results regarding drug candidate VK2735.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
